Key result
Mission Cholesterol 3-in-1 point-of-care testing shows high agreement with laboratory lipid assays.
Why the study?
Comprehensive analytical validation of point-of-care lipid testing devices against reference laboratory methods remains limited.
Does the Mission Cholesterol 3-in-1 point-of-care testing system provide reliable analytical agreement and diagnostic accuracy compared with reference laboratory testing for lipid profiles and atherogenic ratios in adults undergoing routine lipid screening?
Cross-Sectional (n=120)
Independent operators performed laboratory-based and point-of-care measurements
No
Does the Mission Cholesterol 3-in-1 point-of-care testing system provide reliable analytical agreement and diagnostic accuracy compared with reference laboratory testing for lipid profiles and atherogenic ratios in adults undergoing routine lipid screening?
Answers are grounded in this paper and cite their sources.
The Mission Cholesterol 3-in-1 point-of-care analyzer shows strong diagnostic sensitivity and good-to-excellent analytical agreement with laboratory reference standards, supporting its use as a rapid dyslipidemia and cardiometabolic screening tool in resource-limited settings despite modest systematic bias.
Background: Point-of-care testing (POCT) devices offer a rapid alternative for lipid assessment, but comprehensive analytical validation against reference laboratory methods remains limited. Objective: This study aimed to evaluate the agreement, systematic bias, and diagnostic performance of the Mission® Cholesterol 3-in-1 system for lipid profile measurements and atherogenic ratios. Methods: A prospective cross-sectional agreement study was conducted among 120 participants. Lipid profiles were measured using eleven Mission® Cholesterol 3-in-1 analyzers and compared with those measured using the reference laboratory method. Agreement was assessed using the intraclass correlation coefficient (ICC), concordance correlation coefficient (CCC), coefficient of determination (R2), root mean square error (RMSE), mean absolute error (MAE), percentage bias, Bland–Altman plots, Passing–Bablok regression, and diagnostic accuracy. Results: Triglycerides demonstrated excellent agreement (ICC = CCC = 0.972; bias = 5.19%), whereas total cholesterol, HDL-C, non-HDL-C, and LDL-C showed good agreement (ICC range: 0.817–0.854). Among the atherogenic ratios, TG/HDL-C (ICC = 0.932) and TG/LDL-C (ICC = 0.931) exhibited the highest concordance. Passing–Bablok regression revealed constant bias for all analytes, except for LDL-C estimated using the Sampson equation and the TG/LDL-C ratio, while proportional bias was observed for all analytes, except for triglycerides and the TG/LDL-C ratio. Despite these systematic differences, diagnostic performance remained excellent, with sensitivities of 94.29–98.33% and specificities of 68.33–91.80%. Conclusion: The Mission® Cholesterol 3-in-1 system shows good analytical agreement with laboratory testing, particularly for triglycerides and the HDL-C, TG/HDL-C, and TG/LDL-C ratios. Although systematic bias limits complete interchangeability with reference methods, its excellent diagnostic performance supports its use as a rapid point-of-care screening tool, especially in resource-limited settings.
No takes yet. Share an insight, caveat, or question.
Guzmán-Aquino et al. (2026) conducted a cross-sectional in Routine lipid profile testing / Dyslipidemia screening (n=120). Point-of-care lipid testing with the Mission Cholesterol 3-in-1 system vs. Standardized reference laboratory method (iLab Taurus Plus analyzer) was evaluated on Analytical agreement and diagnostic performance for lipid profile measurements and atherogenic ratios. The Mission Cholesterol 3-in-1 system demonstrated good-to-excellent agreement with laboratory lipid testing and high sensitivity for dyslipidemia classification.
Synapse has enriched 10 related papers. Consider them for comparative context: